Daplusiran

Highest phase reached
Phase 1
www.ebi.ac.uk
Drug type
Oligonucleotide
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 1
www.ebi.ac.uk

Drug type
Oligonucleotide
www.ebi.ac.uk
Drug name
Daplusiran
www.ebi.ac.uk

  • daplusiran
  • Daplusiran
  • daplusiran [INN]
  • DAPLUSIRAN [USAN]
  • Daplusiran [WHO-DD]
  • daplusiran inn
  • daplusiran usan
  • daplusiran who dd
  • rna am sp 2 deoxy 2 fluoro g sp am sp 2 deoxy 2 fluoro a am 2 deoxy 2 fluoro a um 2 deoxy 2 fluoro u gm 2 deoxy 2 fluoro a gm 2 deoxy 2 fluoro a gm 2 deoxy 2 fluoro a am 2 deoxy 2 fluoro g um 2 deoxy 2 fluoro c cm am sp cm complex with rna 1 de 6 amino 9h purin 9 yl da 5 5 sp gm um gm gm am cm um um 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u 2 deoxy 2 fluoro c um cm am am um um um um cm um 3 3 sp 1 de 6 amino 9h purin 9 yl da 3 o cis 4 3s 8s 17 2 acetylamino 2 deoxy beta d galactopyranosyl oxy 3 8 bis 2 2 2 acetylamino 2 deoxy beta d galactopyranosyl oxy ethoxy ethyl amino carbonyl 1 6 11 trioxo 15 oxa 2 7 12 triazaheptadec 1 yl cyclohexyl hydrogen phosphorothioate 1 1
  • RNA, (AM-SP-(2'-DEOXY-2'-FLUORO)G-SP-AM-SP-(2'-DEOXY-2'-FLUORO)A-AM-(2'-DEOXY-2'-FLUORO)A-UM-(2'-DEOXY-2'-FLUORO)U-GM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)A-AM-(2'-DEOXY-2'-FLUORO)G-UM-(2'-DEOXY-2'-FLUORO)C-CM-AM-SP-CM), COMPLEX WITH RNA ((1'-DE(6-AMINO-9H-PURIN-9-YL))DA-(5'->5')-SP-GM-UM-GM-GM-AM-CM-UM-UM-(2'-DEOXY-2'-FLUORO)C-(2'-DEOXY-2'-FLUORO)U-(2'-DEOXY-2'-FLUORO)C-UM-CM-AM-AM-UM-UM-UM-UM-CM-UM-(3'->3')-SP-(1'-DE(6-AMINO-9H-PURIN-9-YL))DA) 3'-(O-(CIS-4-((3S,8S)-17-((2-(ACETYLAMINO)-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-3,8-BIS(((2-(2-((2-(ACETYLAMINO)-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)ETHOXY)ETHYL)AMINO)CARBONYL)-1,6,11-TRIOXO-15-OXA-2,7,12-TRIAZAHEPTADEC-1-YL)CYCLOHEXYL) HYDROGEN PHOSPHOROTHIOATE) (1:1)

CAS registry numbers
  • 2202783-35-3
ChEMBL ID
CHEMBL5095455
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • HP2ZTB8W0F

First in class
No
Orphan designation
No

Investigated indications

  • Condition
    Hepatitis B, Chronic
    Highest recorded phase
    1
    Condition identifier
    EFO:0004197
    Subject identifier
    D019694

  • Condition identifier
    EFO_0004197
  • Condition identifier
    MONDO_0005344

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

Sequences

  • Component
    Sequence
    Type
    Nucleic Acid
    Sequence
    (3'-5') R=G-U-G-G-A-C-U-U-C-U-C-U-C-A-A-U-U-U-U-C-U1 (5'-3') C-A-C-C-U-G-A-A-G-A-G-A-G-U-U-A-A-A-A-G-A

Related records

Trials (1)

In development for (1)